The quality of evidence (study allocation and blinding biases) within each subgroup analysis varied greatly. Quality of evidence for all 7 studies on tapering doses of buprenorphine was assessed as low or very low. Quality of evidence for studies of methadone versus buprenorphine was considered low for all outcomes except "number of patients who completed treatment."
In the buprenorphine vs a2-adrenergic agonists group, the quality of evidence was considered moderate for 3 outcomes: mean withdrawal scores, mean days in treatment, and number of patients who completed treatment. These 14 studies demonstrated significant variation in their treatment protocols, medication dosing, study design, study location, and route of medication administration. department (ED): 10 studies occurred in inpatient detoxification clinics and 4 occurred in outpatient clinics. Most studies treated patients with oral medication doses, but a few studies included intramuscular clonidine (1), intramuscular buprenorphine (2), and transdermal clonidine (2). Medication dosing, along with ancillary medications to treat withdrawal adverse effects, also varied across the 14 studies.
Subgroup results revealed that patients treated with buprenorphine had lower overall withdrawal scores and a greater number of days in treatment compared with patients treated with clonidine (Table) . For buprenorphine and methadone subgroups, results suggested similar rates of treatment completion (risk ratio 1.04; 95% confidence interval 0.9 to 1.2).
Commentary
During the last 20 years, the opioid epidemic has surged significantly, and by 2015, approximately 63% of 52,400 drug overdose deaths were related to opioids. 3 Additionally, opioidrelated ED visits have increased by almost 8% annually during 10 years. 4 Treating opioid use disorder is a multimodal process with interventions that occur in various health care settings. The ED serves as an essential transition point for opioid use disorder patients presenting with overdose, acute withdrawal, or associated medical complications.
This systematic review suggests that treatment of acute opioid withdrawal with buprenorphine is superior at decreasing the withdrawal syndrome and keeping patients in treatment longer compared with clonidine. The results suggest that the number needed to treat is 4 with buprenorphine for 1 additional patient to reach withdrawal treatment completion compared with clonidine. However, there was substantial clinical heterogeneity with respect to medication dose, dosing frequency, clinical treatment setting, and administration route. Thus, the subgroup analysis must be interpreted with caution, given that patient treatment regimen and adjunctive medication availability may affect treatment completion. Additionally, the included studies were conducted outside the ED.
Despite these limitations, initiating buprenorphine in the ED may decrease the acute withdrawal syndrome better than current symptom-based therapies, reduce illicit opioid use, and protect patients from opioid overdose. [5] [6] [7] Although methadone and buprenorphine appear to have similar treatment success, the safety, ease of administration, and referral options of the latter may make it a better EDbased treatment. 5, 6 Perhaps most consequentially, initiating buprenorphine in the ED bridges patients to medication-assisted treatment, particularly if coordinated treatment follow-up is used (a "warm handoff"). 8 In summary, studies comparing buprenorphine and clonidine suggest that buprenorphine treatment improves withdrawal scores and number of days in treatment for patients with opioid abuse disorder. Ideally, buprenorphine treatment initiation should not be delayed until the patient accesses a treatment program or requires an inpatient hospital admission. 
